Relay Therapeutics (RLAY) news
Recent news
X-Chem announces phase 3 milestone in collaboration with Relay Therapeutics
X-Chem Pharmaceuticals has announced the achievement of a phase 3 milestone in its ongoing collaboration with Relay Therapeutics, marking a significant step in the development of a novel therapeutic candidate. The milestone, which pertains to the completion of a key preclinical study, was reached…
AInvest Wire · Sep 22, 2026Relay Therapeutics - increases at-the-market offering program to $462.98 mln - SEC filing
AInvest Wire · Aug 6, 2026ImportantRelay Therapeutics shares extend gains to rally 14%
AInvest Wire · Jun 2, 2026Relay Therapeutics 22.9M shares at $12.00/shr
Relay Therapeutics has announced plans to offer 22.9 million shares at a price of $12.00 per share. The offering is part of the company’s broader strategy to raise capital for ongoing operations and research and development initiatives. The terms of the offering, including the number of shares and…
AInvest Wire · May 21, 2026Relay Therapeutics prices offering of stock
Relay Therapeutics, Inc. (Nasdaq: RLAY) has announced the pricing of a public offering of 11,320,755 shares of its common stock at $26.50 per share, with gross proceeds expected to reach approximately $300.0 million before underwriting discounts and expenses. The company also granted the…
AInvest Wire · May 21, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.